Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1 Trial

Business Wire December 8, 2014

Alnylam to Webcast Presentation at the Oppenheimer 25th Annual Healthcare Conference

Business Wire December 3, 2014

New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists

Business Wire December 1, 2014

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Business Wire November 25, 2014

Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014

Business Wire November 17, 2014

Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients

Business Wire November 14, 2014

Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections

Business Wire November 11, 2014

Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference

Business Wire November 6, 2014

Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress

Business Wire November 5, 2014

Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis

Business Wire November 5, 2014

Alnylam to Webcast Presentation at the Nomura Biotechnology Conference

Business Wire October 30, 2014

Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial Results

Business Wire October 29, 2014

Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development

Business Wire October 29, 2014

Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia

Business Wire October 28, 2014

Alnylam Launches Alnylam Assist(TM), Dedicated to Providing Support to Patients, Families, and Caregivers in Certain Genetic Diseases

Business Wire October 20, 2014

Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting

Business Wire October 14, 2014

Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

Business Wire October 13, 2014

Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias

Business Wire October 1, 2014

Alnylam to Webcast Presentation at Leerink Partners Rare Disease Roundtable

Business Wire September 24, 2014

Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis

Business Wire September 24, 2014